Search Results - "Yu, H.A"

EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer by Hastings, K., Yu, H.A., Wei, W., Sanchez-Vega, F., DeVeaux, M., Choi, J., Rizvi, H., Lisberg, A., Truini, A., Lydon, C.A., Liu, Z., Henick, B.S., Wurtz, A., Cai, G., Plodkowski, A.J., Long, N.M., Halpenny, D.F., Killam, J., Oliva, I., Schultz, N., Riely, G.J., Arcila, M.E., Ladanyi, M., Zelterman, D., Herbst, R.S., Goldberg, S.B., Awad, M.M., Garon, E.B., Gettinger, S., Hellmann, M.D., Politi, K.

“…Although EGFR mutant tumors exhibit low response rates to immune checkpoint blockade overall, some EGFR mutant tumors do respond to these therapies; however,…”
Get full text

Fundamental studies of the adhesion of explosives to textile and non-textile surfaces by Yu, H.A, Becker, T, Daeid, N. Nic, Lewis, S.W

“…Graphical abstract…”
Get full text

EGFR Exon 20 Alterations in Lung Adenocarcinomas and Their Impact on Overall Survival and Response to EGFR TKI by Naidoo, J, Sima, C.S, Rodriguez, K, Busby, N, Arcila, M.E, Yu, H.A

Get full text

Post-dural puncture headache after spinal anesthesia and perioperative blood pressure by Chung, J.M, Kim, J.K, Kim, J.Y, Park, K.I, Yu, H.A

Get full text

Pattern of Failure in Metastatic EGFR-Mutant NSCLC Treated With Erlotinib: A Role for Upfront Radiation Therapy? by Patel, S, Rimner, A, Foster, A, Zhang, Z, Woo, K.M, Yu, H.A, Riely, G.J, Wu, A.J

Get full text

Risk of Brain Metastasis in EGFR-Mutant NSCLC Treated With Erlotinib: A Role for Prophylactic Cranial Irradiation? by Patel, S, Rimner, A, Foster, A, Zhang, Z, Woo, K.M, Yu, H.A, Riely, G.J, Wu, A.J

Get full text

Pattern of Failure in Metastatic EGFR-Mutant NSCLC Treated With Erlotinib: A Role for Upfront Radiation Therapy? by Patel, S, Rimner, A, Foster, A, Zhang, Z, Woo, K.M, Yu, H.A, Riely, G.J, Wu, A.J

Get full text

Risk of Brain Metastasis in EGFR-Mutant NSCLC Treated With Erlotinib: A Role for Prophylactic Cranial Irradiation? by Patel, S, Rimner, A, Foster, A, Zhang, Z, Woo, K.M, Yu, H.A, Riely, G.J, Wu, A.J

Get full text

10LBA Interim phase 2 results of study CO-1686-008: A phase 1/2 study of the irreversible, mutant selective, EGFR inhibitor rociletinib (CO-1686) in patients with advanced non small cell lung cancer by Soria, J, Sequist, L.V, Goldman, J.W, Wakelee, H.A, Gadgeel, S.M, Varga, A, Yu, H.A, Solomon, B.J, Ou, S.H, Papadimitrakopoulou, V, Oxnard, G.R, Horn, L, Dziadziuszko, R, Chao, B, Spira, A.I, Liu, S, Mekhail, T, Matheny, S, Litten, J, Camidge, R.D

Get full text

Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib by Schoenfeld, A.J., Arbour, K.C., Rizvi, H., Iqbal, A.N., Gadgeel, S.M., Girshman, J., Kris, M.G., Riely, G.J., Yu, H.A., Hellmann, M.D.

“…Concurrent programmed death-ligand-1 (PD-(L)1) plus osimertinib is associated with severe immune related adverse events (irAE) in epidermal growth factor…”
Get full text

1190TiP Pharmacokinetics, efficacy, and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC) by Yu, H.A., Cantero, F., Kim, B., Lee, M., Wu, E., Sternberg, D.W., Jänne, P.A.

Get full text

COVID-19 in patients with lung cancer by Luo, J., Rizvi, H., Preeshagul, I.R., Egger, J.V., Hoyos, D., Bandlamudi, C., McCarthy, C.G., Falcon, C.J., Schoenfeld, A.J., Arbour, K.C., Chaft, J.E., Daly, R.M., Drilon, A., Eng, J., Iqbal, A., Lai, W.V., Li, B.T., Lito, P., Namakydoust, A., Ng, K., Offin, M., Paik, P.K., Riely, G.J., Rudin, C.M., Yu, H.A., Zauderer, M.G., Donoghue, M.T.A., Łuksza, M., Greenbaum, B.D., Kris, M.G., Hellmann, M.D.

“…Patients with lung cancers may have disproportionately severe coronavirus disease 2019 (COVID-19) outcomes. Understanding the patient-specific and…”
Get full text

1195TiP HERTHENA-Lung02: A randomized phase III study of patritumab deruxtecan vs platinum-based chemotherapy in locally advanced or metastatic EGFR-mutated NSCLC after progression with a third-generation EGFR TKI by Mok, T.S.K., Wu, Y-L., Nishio, M., Reck, M., Wu, E., Sternberg, D.W., Esker, S., Yu, H.A.

Get full text

Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing by Yu, H.A., Arcila, M.E., Hellmann, M.D., Kris, M.G., Ladanyi, M., Riely, G.J.

“…EGFR T790M is the most common mutation associated with acquired resistance to EGFR tyrosine kinase inhibitors (TKIs). Baseline EGFR T790M mutations in EGFR…”
Get full text

1345P Preliminary safety and activity of CLN-081 in NSCLC with EGFR exon 20 insertion mutations (Ins20) by Piotrowska, Z., Nguyen, D., Koczywas, M., Tchekmedyian, N., Clancy, M.S., Witter, D., Page, A., Zawel, L., Yu, H.A.

Get full text

329P ORCHARD: Osimertinib + necitumumab in patients (pts) with advanced NSCLC whose disease progressed on first-line (1L) osimertinib by Riess, J.W., De Langen, J.A., Piotrowska, Z., Goldberg, S.B., Goldman, J.W., Okamoto, I., Ponce Aix, S., Teraoka, S., Ambrose, H., Tang, K.H., Maidment, J., Merchan Ruiz, B., Hewson, N., Cosaert, J., Yu, H.A.

Get full text

APOBEC mutagenesis, kataegis, chromothripsis in EGFR-mutant osimertinib-resistant lung adenocarcinomas by Selenica, P., Marra, A., Choudhury, N.J., Gazzo, A., Falcon, C.J., Patel, J., Pei, X., Zhu, Y., Ng, C.K.Y., Curry, M., Heller, G., Zhang, Y.-K., Berger, M.F., Ladanyi, M., Rudin, C.M., Chandarlapaty, S., Lovly, C.M., Reis-Filho, J.S., Yu, H.A.

“…Studies of targeted therapy resistance in lung cancer have primarily focused on single-gene alterations. Based on prior work implicating apolipoprotein b…”
Get full text

1188TiP ORCHARD platform study: Osimertinib + datopotamab deruxtecan (Dato-DXd) cohort in patients (pts) with advanced NSCLC (aNSCLC) who have progressed on first-line (1L) osimertinib by De Langen, J., Cho, B.C., Piotrowska, Z., Le, X., Goldberg, S.B., Goldman, J.W., Okamoto, I., Hewson, N., Maidment, J., Tang, K.H., Veney, N., Cosaert, J., Lau, J., Dressman, M., Ambrose, H., Riess, J.W., Yu, H.A.

Get full text

13P Durvalumab + chemotherapy in patients (pts) with advanced EGFR mutation-positive (EGFRm) NSCLC whose disease progressed on first-line (1L) osimertinib: An ORCHARD study interim analysis by Cho, B.C., Ahn, M-J., Baik, C., García, R., Goldman, J.W., Kim, S-W., Lee, J.S., Nishio, M., Ponce, S., Salgia, R., Teraoka, S., Yoshida, T., Yu, H.A., Ambrose, H., Cosaert, J., Hartmaier, R., Maidment, J., Pluta, M., Okamoto, I.

Get full text

1319MO Intracranial efficacy of HER3-DXd in patients with previously treated advanced EGFR-mutated NSCLC: Results from HERTHENA-Lung01 by Johnson, M.L., Jänne, P.A., Goto, Y., Yoh, K., Lee, S-H., Paz-Ares, L., Besse, B., Novello, S., Hayashi, H., Kim, D-W., John, T., Kao, S.C-H., Felip, E., Yang, J.C-H., Reck, M., Dong, Q., Sporchia, A., Sternberg, D.W., Yu, H.A.

Get full text